The role of blinatumomab followed by HSCT in paediatric patients with ALL
Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy
The role of blinatumomab followed by HSCT in paediatric patients with ALL ( Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy )
23 Jan 2020
Defining the role of immunotherapy in B-cell ALL
Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy
Defining the role of immunotherapy in B-cell ALL ( Prof Franco Locatelli - Ospedale Pediatrico Bambino Gesù, Rome, Italy )
23 Jan 2020
Long-term toxicities in paediatric ALL
Prof Kjeld Schmiegelow - University of Copenhagen, Copenhagen, Denmark
Long-term toxicities in paediatric ALL ( Prof Kjeld Schmiegelow - University of Copenhagen, Copenhagen, Denmark )
23 Jan 2020
How is minimal residual disease managed in patients with ALL?
Dr Renato Bassan - Ospedale dell'Angelo & Ospedale SS, Venice, Italy
How is minimal residual disease managed in patients with ALL? ( Dr Renato Bassan - Ospedale dell'Angelo & Ospedale SS, Venice, Italy )
23 Jan 2020
BLAST: Blinatumomab for minimal residual disease in patients with ALL
Dr Renato Bassan - Ospedale dell'Angelo & Ospedale SS, Venice, Italy
BLAST: Blinatumomab for minimal residual disease in patients with ALL ( Dr Renato Bassan - Ospedale dell'Angelo & Ospedale SS, Venice, Italy )
23 Jan 2020
Frontline therapy of ALL
Prof Hervé Dombret - University Paris Diderot, Paris, France
Frontline therapy of ALL ( Prof Hervé Dombret - University Paris Diderot, Paris, France )
23 Jan 2020
BiTE therapy followed by HSCT vs CAR-T cells in young patients with R/R ALL
Prof Hervé Dombret - University Paris Diderot, Paris, France
BiTE therapy followed by HSCT vs CAR-T cells in young patients with R/R ALL ( Prof Hervé Dombret - University Paris Diderot, Paris, France )
23 Jan 2020
Treatment of Ph-negative ALL in adolescents and young adults
Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain
Treatment of Ph-negative ALL in adolescents and young adults ( Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain )
23 Jan 2020
The new era of ALL treatment
Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain
The new era of ALL treatment ( Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain )
23 Jan 2020
Safety considerations for inotuzumab in patients with relapsed/refractory ALL
Prof David Marks - University Hospitals Bristol NHS Foundation Trust, Bristol, U...
Safety considerations for inotuzumab in patients with relapsed/refractory ALL ( Prof David Marks - University Hospitals Bristol NHS Foundation Trust, Bristol, UK )
23 Jan 2020
Identifying cancer susceptibility genes in paediatric ALL
Dr Ching-Hon Pui - St Jude's Children's Research Hospital, Memphis, USA
Identifying cancer susceptibility genes in paediatric ALL ( Dr Ching-Hon Pui - St Jude's Children's Research Hospital, Memphis, USA )
23 Jan 2020
Defining high-risk acute lymphoblastic leukaemia
Dr Ching-Hon Pui - St Jude's Children's Research Hospital, Memphis, USA
Defining high-risk acute lymphoblastic leukaemia ( Dr Ching-Hon Pui - St Jude's Children's Research Hospital, Memphis, USA )
23 Jan 2020